Stilbenes: A Molecular Docking and ADMET Analysis Approach on an Emerging Resource for Scavenging Reactive Oxygen Species in the Field of Colon Malignancy


Year : 2024 | Volume : 14 | Issue : 03 | Page : 29-38
    By

    Aayushi Chaudhuri,

  1. Student, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India

Abstract

Objective: Colon malignancy, also referred to as colon cancer, originates as precancerous polyps in the colon or rectum, which have the potential to thrive and progress into cancerous tumors over time. This study delves into various bioactive compounds (from natural sources like plants) to assess their potential efficacy in inhibiting colon malignancy as compared to conventional methods. Methods: The objective of this study was to employ computational methodologies to evaluate the efficacy of various stilbenes against TRAF2, a protein associated with colon cancer. Molecular docking was systematically conducted using the virtual screening tool PyRx. Among the screened natural compounds, the top candidates were selected to assess their compatibility with TRAF2. Pharmacological evaluation of the ligands was performed utilizing ADMET filters. Result: The compounds resveratrol 4’-glucoside, gnetin C, and resveratrol 5-O-glucoside were identified as the most potential ROS for colon cancer treatment against the TRAF2 protein. Conclusion: All these bioactive substances are potential candidates for inhibiting colon cancer, given their significant binding affinity for the protein. Notably, among the top ligands, resveratrol 4’-glucoside, gnetin C, and resveratrol 5-O-glucoside exhibited superior binding to the target protein.

Keywords: Colon malignancy, stilbenes, TRAF2 protein, ADMET filters, Molecular Docking

[This article belongs to Research & Reviews : A Journal of Biotechnology (rrjobt)]

How to cite this article:
Aayushi Chaudhuri. Stilbenes: A Molecular Docking and ADMET Analysis Approach on an Emerging Resource for Scavenging Reactive Oxygen Species in the Field of Colon Malignancy. Research & Reviews : A Journal of Biotechnology. 2024; 14(03):29-38.
How to cite this URL:
Aayushi Chaudhuri. Stilbenes: A Molecular Docking and ADMET Analysis Approach on an Emerging Resource for Scavenging Reactive Oxygen Species in the Field of Colon Malignancy. Research & Reviews : A Journal of Biotechnology. 2024; 14(03):29-38. Available from: https://journals.stmjournals.com/rrjobt/article=2024/view=181289


Browse Figures

References

1. Sanford DM, Dawn MD, Willis J, James KV. Focus on colon cancer. Cancer Cell. 2002;1(3):233–236. doi:10.1016/S1535-6108(02)00053-3.
2. Burt RW. Colon cancer screening. Gastroenterol. 2000;119(3):837–853. doi:10.1053/gast.2000.16508.
3. Rimando AM, Suh N. Biological/chemo preventive activity of stilbenes and their effect on colon cancer. Planta Med. 2008;74(13):1635–1643. doi:10.1055/s-0028-1088301.
4. Nutakul W, Sobers HS, Qiu P, Dong P, Decker EA, McClements DJ, Xiao H. Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: A side by side comparison. J Agric Food Chem. 2011;59(20):10964–10970. doi:10.1021/jf202846b.
5. Ahnen DJ. Genetics of colon cancer. West J Med. 1991;154(6):700–705.
6. Slattery ML, Pellatt DF, Mullany LE, Wolff RK, Herrick JS. Gene expression in colon cancer: A focus on tumor site and molecular phenotype. Genes Chromosomes Cancer. 2015;54(9):527–541. doi:10.1002/gcc.22265.
7. Nyström M, Mutanen M. Diet and epigenetics in colon cancer. World J Gastroenterol. 2009;15(3): 257–263. doi:10.3748/wjg.15.257.
8. Valinluck VL and Grady WM. Epigenetics and Colorectal Cancer. Nat Rev Gastroenterol Hepatol; 8(12): 686–700.
9. Sreevalsan S, Stephen S. Reactive oxygen species and colorectal cancer. Curr Colorectal Cancer Rep. 2013;9(4):350–357. doi:10.1007/s11888-013-0190-5.
10. Colin DJ, Limagne E, Ragot K, Lizard G, Ghiringhelli F, Solary E, Chauffert B, Latruffe N, Delmas D. The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models. Cell Death Dis. 2014;5:e1533. doi:10.1038/cddis.2014.486.
11. Ahmad R, Singh JK, Wunnava A, Obeed OA, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: Dysregulated signaling pathways. Int J Mol Med. 2021;47(14). doi:10.3892/ijmm.2021.4847.
12. Jannah LR, Sanjaya GM. Colon Cancer drug development study of ellagic acid derivatives. J Kimia. 2021;15(2):215–222. doi:10.24843/JCHEM.2021.v15.i02.p13.
13. Dallakyan S, Olson AJ. Small-Molecule Library Screening by Docking with PyRx. In: Hempel J, Williams C, Hong C, editors. Chemical Biology. Methods in Molecular Biology. New York: Humana Press; 20015. 243–250. doi:10.1007/978-1-4939-2269-7_19.
14. Sharma S, Sharma A, Gupta U. Molecular docking studies on the anti-fungal activity of Allium sativum (Garlic) against Mucormycosis (black fungus) by BIOVIA discovery studio visualizer 21.1. 0.0. Ann Antivir Antiretrovir. 2021;5(1):28–32. doi:10.21203/rs.3.rs-888192/v1.
15. Zhou AQ, Corey S, O’Hern, Regan L. Revisiting the Ramachandran plot from anew angle. Protein Sci. 2011;20(7):1166–1171. doi:10.1002/pro.644.
16. Sudhakar A. History of cancer, ancient and modern treatment methods. J Cancer Sci Ther. 2009;1(2):1–4.
17. Schulmann K, Reiser M, Schmiegel W. Colonic cancer and polyps. Best Pract Res Clin. Gastroenterol. 2002;16(1):91–114. doi:10.1053/bega.2002.0268.
18. Suleyman K, Abdullah S, Fatih B, Mustafa H, Ali K, Koray K, Ediz KA, Ilyas K, Gurhan B, Orhan A. Evaluating factors affecting survival in colon and rectum cancer. J Cancer Res Therapeutics. 2018;14(2):416–420. doi:10.4103/0973-1482.199390.
19. Mishra J, Dromund J, Quazi SH, Karanki SS, Shaw JJ, Chen B, and Kumar N. Prospective of colon cancer treatments and scope for combinatorial approach to enhance cancer cell apoptosis. Crit Rev Oncol Hematol. 2013;86(3):232–250. doi:10.1016/j.critrevonc.2012.09.014.
20. Huang L, Zhang S, Zhou J, Xiangzhou L. Effect of resveratrol on drug resistance in colon cancer chemotherapy. Royal Soc Chem. 2019;9:2572–2580. doi:10.1039/C8RA08364A.
21. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311–335. doi:10.1021/np200906s.
22. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200–216. doi:10.1038/s41573-020-00114-z.


Regular Issue Subscription Original Research
Volume 14
Issue 03
Received 02/09/2024
Accepted 24/10/2024
Published 06/11/2024


Loading citations...